Experience with E. coli lyophilized bacterial lysate OM-89 (Uro-Vaksom®) in men with asymptomatic bacteriospermia
- Authors: Pochernikov DG1, Jakovleva LV1, Strelnikov AI1, Vinokurov EJ.1, Boldin DI1
-
Affiliations:
- Ivanovo State Medical Academy
- Issue: No 4 (2015)
- Pages: 84-89
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/281837
- ID: 281837
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
Chronic prostatitis is a significant problem of modern urology because it is the most common urological disease among the male population. We consider a 3 month course of OM-89 (Uro-Vaksom®) the most rational treatment of asymptomatic bacteriospermia caused by not only
E. coli, but also by coexisting bacteria. Administration of OM-89 (Uro- Vaksom®) for 3 months to patients with asymptomatic bacteriospermia resulted in greater E. coli eradication in 98% of men and no growth of microorganisms in the ejaculate in 66%. Compared to these results, after a 3-4 week course of fluoroquinolones, E. coli occurred in significant titer in 15.2%, in non-significant - in 5.7% and the absence of microbial growth was noted only in 19% of cases. The course of OM-89 (Uro- Vaksom®), compared with fluoroquinolones, resulted in significantly increased sperm concentration and occurrence of greater number of spontaneous pregnancies. Rate of THB (Take Home Baby) for OM-89 (Uro-Vaksom®) group was 21%, for fluoroquinolones treatment group - 7%.
E. coli, but also by coexisting bacteria. Administration of OM-89 (Uro- Vaksom®) for 3 months to patients with asymptomatic bacteriospermia resulted in greater E. coli eradication in 98% of men and no growth of microorganisms in the ejaculate in 66%. Compared to these results, after a 3-4 week course of fluoroquinolones, E. coli occurred in significant titer in 15.2%, in non-significant - in 5.7% and the absence of microbial growth was noted only in 19% of cases. The course of OM-89 (Uro- Vaksom®), compared with fluoroquinolones, resulted in significantly increased sperm concentration and occurrence of greater number of spontaneous pregnancies. Rate of THB (Take Home Baby) for OM-89 (Uro-Vaksom®) group was 21%, for fluoroquinolones treatment group - 7%.
About the authors
D G Pochernikov
Ivanovo State Medical AcademyIvanovo State Medical Academy
L V Jakovleva
Ivanovo State Medical AcademyIvanovo State Medical Academy
A I Strelnikov
Ivanovo State Medical AcademyIvanovo State Medical Academy
E Ju Vinokurov
Ivanovo State Medical AcademyIvanovo State Medical Academy
D I Boldin
Ivanovo State Medical AcademyIvanovo State Medical Academy
References
- Murphy A.B., Macejko A., Taylor A., Nadler R.B. Chronic prostatitis: management strategies. Drugs. 2009;69(1):71-84. 2.
- АляевЮ.Г., Глыбочко П.Б., Пушкарь Д.Ю. Урология. Российские клинические рекомендации. М., 2015.
- Гориловский Л.М., Зингеренко М.Б. Хронический простатит. Лечащий врач. 2003;7: 21-26.
- Alexander R.B., Brady F, Ponniah S. Autoimmune prostatitis: evidence of T cell reactivity with normal prostatic proteins. Urology. 1997;50:893-899.
- Jungwirth A., Diemer T, Dohle G.R. et al. Guidelines on Male Infertility. Eur. Ass. Urol. 2014. 6.
- Урология. Клинические рекомендации. Под ред. Н.А. Лопаткина. 2-е изд. М.: ГЭОТАР-Медиа, 2013. 7.
- McNaughton Collins M., Fowler Jr.F.J, Elliot D.B., Albertsen P.C., Barry M.J. Diagnosing and treating chronic prostatitis: do urologists use the four-glass test? Urology. 2000;55:403-407.
- Локшин К.Л. Актуальные вопросы антибиотикотерапии простатитов. Урология. 2014;1:55-61.
- Кульчавеня Е.В., Бреусов А.А. Эффективность уроваксома при рецидивирующих инфекционно-воспалительных заболеваниях мочеполовой системы. Урология. 2011;4:7-11.
- Лямин Б.А., Ощепков В.П., Дарий Е.В. Комплексная терапия больных хроническим инфекционным простатитом с применением препарата уроваксом. Материалы 2-й Всероссийской конференции «Мужское здоровье». М., 2005.С. 303.
- Wagenlehner F.M., Ballarini S., Naber K.G. Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one-year prospective, double-blind, placebo-controlled study. World J. Urol. 2014;32(6):1595 -1603.
- Тихомиров А.Л., Олейник Ч.Г. Бактериальный вагиноз: некоторые аспекты этиологии, патогенеза, клиники, диагностики и лечения. Гинекология. 2004;2:62-65.
- Pham T.V., Kreis B., Corradin-Betz S., Bauer J., Mauer J. Metabolitic and functional stimulation of lymphocytes and macrophages by an Escherichia coli extract (OM-89): in vitro studies. J. Bion. Response Mod. 1990;9:231-240.
- Hockertz St. Immunomodulatory effects of immunoactive fractions of selected Escherichia coli strains on the macrophage. Arzneim. Forsch. Drug. Res. 1990;143:759-763.
- Bottex С., Cristau B., Corraza J.L., Mougin B., Fontange R. Effects of two bacterial extracts, OM-89 and Broncho-Vaxom, on IL-1 release and metabolic activity of a murine macrophage cell-line. Int. J. Immunotherapy. 1998;4:203-212.
- Wybran J., Libin M., Schandene L. Enhancement of cytokine production and natural killer activity by an Escherichia coli extract. Oncologie. 1989;12:22-25.
- Bessler W.G., vor dem Esche U., Zgaga-Griesz A., Ataullakhanov R. Immunostimulatory properties of the bacterial extract OM-89 in vitro and in vivo. Arzneimittelforschung. 2010;60(6):324-329. 18.
- WHO laboratory manual for the examination of human sperm and semem-cervical mucus interaction. WHO, 4-th ed.: Cambridge universiti press, 1999.
Supplementary files
